Case-control study to evaluate risk factors for the development of sepsis (neutropenia and fever) in dogs receiving chemotherapy

Journal of the American Veterinary Medical Association

Volumn 236, Issue 6, 2010, Pages 650-656

  Sorenmo, Karin U ^a   Harwood, Lisa P ^a,b   King, Lesley G ^a   Drobatz, Kenneth J ^a  

^a UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

^b Paoli Vetcare   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL; ANIMAL DISEASE; ARTICLE; BODY WEIGHT; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; DOG; DOG DISEASE; FEMALE; FEVER; MALE; NEOPLASM; NEUTROPENIA; RETROSPECTIVE STUDY; RISK FACTOR; SEPSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CASE-CONTROL STUDIES; DOG DISEASES; DOGS; FEMALE; FEVER; MALE; NEOPLASMS; NEUTROPENIA; RETROSPECTIVE STUDIES; RISK FACTORS; SEPSIS;

ANIMALIA; CANIS FAMILIARIS;

EID: 77950359270     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.236.6.650     Document Type: Article

References (25)

1. Chun R, Garrett L, Vail D. Cancer chemotherapy. In: Small animal clinical oncology. 4th ed. Philadelphia: Saunders, 2007;163-192.
2. Pizzo PA, Young RC. Infection in the cancer patient. In: De Vita VT, Hellman S, Rosenberg SA, eds. Cancer principles and practice of oncology. 2nd ed. Philadelphia: JB Lippincott Co, 1985;1963-1999.
3. Aschengrau A, Seage G III. Case-control studies. In: Aschengrau A, Seage G, eds. Essentials of epidemiology in public health. 2nd ed. Sudbury, Mass: Jones and Bartlett Publishers, 2007;229-258.
4. Arrington KA, Legendre AM, Tabeling GS, et al. Comparison of body surface area-based and weight-based dosage protocols for doxorubicin administration in dogs. AmJ Vet Res 1994;55:1587-1592.
5. Ogilvie GK, Richardson RC, Curtis CR, et al. Acute and shortterm toxicoses associated with the administration of doxorubicin to dogs with malignant tumors. J Am Vet Med Assoc 1989;195:1584-1587.
6. Price GS, Frazier DL. Use of body surface area (BSA)-based dosages to calculate chemotherapeutic drug dose in dogs. Potential problems with the current BSA formulae. J Vet Intern Med 1998;12:267-271.
7. Ogilvie GK, Moore AS, Curtis CR. Evaluation of cisplatin-induced emesis in dogs with malignant neoplasia: 115 cases (1984-1987). J Am Vet Med Assoc 1989;195:1399-1403.
8. Page RL, Macy DW, Thrall DE, et al. Unexpected toxicity associated with the use of body surface area for dosing melphalan in the dog. Cancer Res 1988;48:288-290.
9. Frazier DL, Price GS. Use of body surface area to calculate chemotherapeutic drug dose in dogs: II. Limitations imposed by pharmacokinetic factors. J Vet Intern Med 1998;12:272-278.
10. Sawyer M, Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs 2001;19:171-177.
11. Baker SD, Verweij J, Rowinsky EK, et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Nail Cancer Inst 2002;94:1883-1888.
12. Walter CU, Biller BJ, Lana SE, et al. Effects of chemotherapy on immune responses in dogs with cancer. J Vet Intern Med 2006;20:342-347.
13. Miniscalco B, Guglielmino R, Morello E, et al. Clinical usefulness of peripheral blood lymphocyte subsets in canine lymphoma. Vet Res Commun 2003;27(suppl 1):407-409.
14. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-748.
15. Crockaert F Febrile neutropenia in children. Int J Antimicrob Agents 2000;16:173-176.
16. Ohe Y, Yamamoto S, Suzuki K, et al. Risk factors of treatment related death in chemotherapy and thoracic radiotherapy for lung cancer. Eur J Cancer 2001;37:54-63.
17. Hamalainen S, Kuittinen T, Matinlauni I. Neutropenic fever and severe sepsis in adult acute myeloid leukemia (AML) patients receiving intensive chemotherapy: causes and consequences. Leuk Lymphoma 2008;49:495-501.
18. Northrup NC, Rassnick KM, Snyder LA, et al. Neutropenia associated with vincristine and L-asparaginase induction chemotherapy for canine lymphoma. J Vet Intern Med 2002;16:570-575.
19. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038-3051.
20. Elting LS, Rubenstein EB, Rolston KVI, et al. Outcome of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Inject Dis 1997;25:247-259.
21. Raad II, Escalante C, Hachem RY. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime. Cancer 2003;98:1039-1047.
22. Chretin JD, Rassnick KM, Shaw NA, et al Prophylactic trimethoprimsulfadiazine during chemotherapy in dogs with lymphoma and osteosarcoma: a double-blind, placebo-controlled study. J Vet Intern Med 2007;21:141-148.
23. Bucaneve G, Micozzi A, Menichetti F Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005;353:977-987.
24. Cullen M, Steven N, Billingham L. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005;353:988-998.
25. Kurt B, Flynn P, Shenep JL. Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia. Cancer 2008;113:376-382.